HCV Care Pathway in Ile-de-France

• Conditions: Hepatitis C Virus
• Interventions: Other: No intervention

• Registration Number: NCT02893046
• Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Brief Summary

The main objective of this research is to evaluate a care pathway adapted to different category populations at risk of being infected with the hepatitis C virus in order to improve both the diagnosis turnaround times and the access to treatment. The aim is to allow a quick and effective access to diagnosis and treatment of HCV by strengthening the city hospital networks, access to early consultations and coordination of medical social actors.

Detailed Description

The current estimation of infected persons with chronic hepatitis C in France is over 200 ,000. It appears that prevention, screening, care management, medical and social care of patients can be significantly improved especially among the most vulnerable populations. Indeed, these new HCV infections are mediated by drug-using people, prisoners, migrants, men who have sex with men (MSM) and who are supported too late and without real access to treatment.

Study Timeline

• Status Verified: 2016-08
• Study First Submitted: 2016-08-25
• Study Start: 2016-09
• Study First Submitted QC: 2016-09-01
• Last Update Submitted: 2016-09-01
• Study First Posted: 2016-09-08
• Last Update Posted: 2016-09-08
• Primary Completion: 2017-09
• Study Completion: 2019-09

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• 18 years old and more
• Positive Hepatitis C virus
• Patient having expressed a non-objection to participate in this research

Exclusion Criteria

None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Prison population	No intervention	Proposal of participation to a " consultation arrivants " by the staff of medical units correctional
Population at Risk	No intervention	Population with at least one risk factor of being infected with hepatitis C; MSM population; people in precarious situations and / or attending support from addictions care structures.

Primary Outcome Measures

Name	Time	Method
Number of patients effectively cared divided by number of patients eligible to care.	Year 3

Secondary Outcome Measures

Name	Time	Method
Number of patients effectively treated divided by number of patients eligible to DAA treatment.	Year 3
Delay between HCV diagnosis and early consultation	Year 3
Number of patients cared in the HCV care pathway in Ile-de-France	Year 3

Trial Locations

Locations (1)

Henri Mondor Hospital; 🇫🇷 Creteil, France